Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 15/20 | 0.58 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1528048 | 0.91 | TLR8 (0.60) | TLR8TLR7MAPTNPSR1KDM4E | |
| SCHEMBL1527953 | 0.90 | TLR7 (0.61) | TLR8TLR7PDE10A | |
| SCHEMBL1527945 | 0.88 | TLR8 (0.56) | TLR8TLR7MAPTKDM4EGAA | |
| SCHEMBL13128115 | 0.85 | TLR8 (0.42) | TLR8TLR7KDM4EALDH1A1GAA | |
| SCHEMBL1528042 | 0.84 | TLR8 (0.44) | TLR8TLR7KDM4EHPGDPDE10A | |
| SCHEMBL5767486 | 0.81 | TLR8 (0.42) | TLR8TLR7PDE10A | |
| SCHEMBL1528109 | 0.81 | TLR8 (0.46) | TLR8TLR7KDM4EPDE10A | |
| SCHEMBL13128117 | 0.81 | TLR8 (0.39) | TLR8TLR7KDM4EPDE10AGPR3 | |
| SCHEMBL1528127 | 0.81 | TLR8 (0.41) | TLR8TLR7MAPTKDM4EHPGD | |
| SCHEMBL1527836 | 0.81 | TLR8 (0.59) | TLR8TLR7MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4662630-B2 | — | — | 2011-03-30 | — | — | JP | claimed |
| US-6809203-B2 | IMMUNOMODULATORS; INDUCING CYTOKINE BIOSYNTHESIS INCLUDING INTERFERON-ALPHA AND/OR TUMOR NECROSIS FACTOR-ALPHA | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-26 | — | — | US | claimed |
| US-20040122041-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-24 | — | — | US | claimed |
| US-20030195224-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4- amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-16 | — | — | US | claimed |
| EP-1100802-B1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLINE-4-AMINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2003-09-24 | — | — | EP | claimed |
| US-20030065006-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | claimed |
| US-20030064968-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | claimed |
| US-20030045545-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-03-06 | — | — | US | claimed |
| JP-2002524392-A | — | — | 2002-08-06 | — | — | JP | claimed |
| US-20020072528-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2002-06-13 | — | — | US | claimed |
| EP-1100802-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M Innovative Properties Company (US) | 2001-05-23 | — | — | EP | claimed |
| WO-2000006577-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-02-10 | — | — | WO | claimed |
| WO-2025103490-A1 | N-OXIDE IMMUNE AGONISTS ACTIVATION BY RADIOTHERAPY | Beijing Changping Laboratory (CN) | 2025-05-22 | — | — | WO | disclosed |
| US-7148232-B2 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1380587-B1 | Oxazolo, thiazolo and selenazolo [4,5-c]naphthyridine-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES CO (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050096259-A1 | Neutrophil activation by immune response modifier compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2005-05-05 | — | — | US | disclosed |
| EP-1100802-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M Innovative Properties Company (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6110929-A | IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| WO-2000006577-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| US-4904669-A | Thiazolo/4,5-c/quinolines as major tranquilizers | EGIS GYOGYSZERGYAR (HU) | 1990-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064968-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | TLR8 290/4885TLR7 109/4885MAPT 3980/4885 |
| US-20020072528-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | TLR8 290/4885TLR7 109/4885MAPT 3980/4885 |
| US-20030065006-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | TLR8 290/4885TLR7 109/4885MAPT 3980/4885 |
| US-20030195224-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4- amines and analogs thereof | IFNG, THPO, IL2 | TLR8 290/4885TLR7 109/4885MAPT 3980/4885 |
| US-20040122041-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | TLR8 290/4885TLR7 109/4885MAPT 3980/4885 |
| US-20030045545-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | TLR8 290/4885TLR7 109/4885MAPT 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.